Non–Daily-Dosed Rosuvastatin in Statin-Intolerant Veterans
Federal Practitioner. 2014 February;31(2):24-28
February 17, 2014|Federal Practitioner
Author and Disclosure Information
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are the treatment of choice for hyperlipidemia.(1) Many patients, however, are unable to tolerate statins and subsequently discontinue therapy. The reported incidence of statin intolerance varies widely in the literature. A recent review estimated that 10% to 15% of statin users experience some type of myopathy, which is one of the most common reasons for discontinuation.(2)
